Table 2 Validation results for the subset of patients from the 20% validation set that includes patients with pretreatment slides only (n = 931).

From: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

Clinical outcome

NCCN AUC estimates (95% CI)

MMAI AUC (95% CI)

Differential AUC estimate (MMAI - NCCN)

Comparative test p-value

Distant Metastasis (5-year)

0.72 (0.67–0.78)

0.83 (0.78–0.88)

0.11

<0.001

Distant Metastasis (10-year)

0.69 (0.64–0.74)

0.78 (0.73–0.84)

0.09

<0.001

Biochemical Failure (5-year)

0.61 (0.57–0.64)

0.69 (0.65–0.73)

0.08

<0.001

Biochemical Failure (10-year)

0.62 (0.58–0.66)

0.68 (0.63–0.72)

0.06

0.004

Prostate Cancer-Specific Survival (10-year)

0.67 (0.61–0.73)

0.77 (0.70–0.83)

0.10

<0.001

Overall Survival (10-year)

0.57 (0.54–0.61)

0.65 (0.61–0.69)

0.08

<0.001

  1. AUC Area under the curve, CI confidence interval, MMAI multimodal artificial intelligence, NCCN National Comprehensive Cancer Network.
Back to article page